Oxygen Biotherapeutics, Inc. Analyst Report: Positive FDA Catalyst Has Emerging Biopharmaceutical Player Back In the Clinical Trial Business

NEW YORK, April 21, 2014 /PRNewswire/ -- Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT), an emerging competitor, is engaged in the business of developing biotechnology products in the nature of blood substitutes with a focus on oxygen delivery to tissue. It is currently developing Oxycyte™, a product which is a safe and effective oxygen carrier for use in surgical and similar medical situations. The Company's Oxycyte oxygen carrier product is a perfluorocarbon emulsified with water and a surfactant, which is provided to the patient intravenously.

Further development of this product is poised to resume after the lifting of a hold by the FDA. Prior to the initiation of any human clinical studies using Oxycyte in the US, the company will need to develop an FDA approved protocol which will incorporate FDA input on the design and safety measures to be utilized in such studies. Oxygen has been enrolling patients outside of the US in a Phase II-b study to evaluate the safety and tolerability of Oxycyte in patients with severe non-penetrating traumatic brain injury (STOP-TBI). The study was recently enrolling patients in Israel for the second cohort of a three cohort trial.

An analyst report which details key attributes of the products, an overview of the company and analyst comments can be viewed in its entirety by using the link below. There is no cost to view this report:

http://bit.ly/OXBT-AnalystResearch

Copy and paste to browser may be required.

FORWARD-LOOKING DISCLAIMER   

This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward- looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.   

COMPLIANCE PROCEDURE   

Content is researched, written and reviewed on a best-effort basis. This document, article or report is written and authored by Michael Andereg, CFA. An outsourced research services provider represented by Michael Andereg, CFA, provided Small Cap Specialists, LLC this article or report. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. Small Cap Specialists, LLC is not entitled to veto, interfere or alter the articles, documents or report once created and reviewed by the outsourced research provider represented by Michael Andereg, CFA.   

If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected]. For any urgent concerns or inquiries, please contact us at [email protected].   

NO WARRANTY OR LIABILITY ASSUMED   

OXBT has not compensated Small Cap Specialists, LLC or Michael Andereg, CFA for the creation or dissemination of this report. Small Cap Specialists, LLC is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. Small Cap Specialists, LLC does not hold any positions in OXBT. No liability is accepted by Small Cap Specialists, LLC whatsoever for any direct, indirect or consequential loss arising from the use of this document. Small Cap Specialists, LLC expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Small Cap Specialists, LLC does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.   

Michael Andereg, CFA, is the author of research report. Information in this release is fact checked and produced on a best efforts basis by Michael Andereg, CFA.   

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

Contact: [email protected]

SOURCE Small Cap Specialists, LLC

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED